Dostarlimab: First Approval
This article summarizes the milestones in the development of dostarlimab leading to these first approvals. (Source: Drugs)
Source: Drugs - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
AbstractImmune checkpoint inhibitors (ICI) have shown important but variable efficacy in mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI monotherapy in patients with relapsed mesothelioma, with objective response rates (ORR) between 4.5 and 29%, median progression-free survival (PFS) between 2.5 –6.2 months, and median overall survival (OS) between 7.7 and 18.0 months. In randomised trials of chemotherapy pre-treated patients, nivolumab was recently shown to improve PFS compared to placebo, but tremelimumab was not superior to placebo, and there was no difference in OS between ...
Source: Drugs - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting
AbstractPostoperative nausea and vomiting (PONV) are the second most frequent adverse events after surgery second only to postoperative pain. Despite the advances in antiemetics and implementation of multimodal prophylactic interventions, the clinical management of PONV remains problematic. Neurokinin-1 (NK-1) receptor is a tachykinin receptor found throughout the central and peripheral nervous systems, with a particular affinity towards substance P. NK-1 receptors interact with several parts of the neuronal pathway for nausea and vomiting. This includes the chemoreceptor trigger zone, the gastrointestinal tract, and dorsa...
Source: Drugs - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Lazertinib: First Approval
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01549-3 (Source: Drugs)
Source: Drugs - June 9, 2021 Category: Drugs & Pharmacology Source Type: research

Current Status of Clinical Trials on Tau Immunotherapies
AbstractTau immunotherapies have advanced from proof-of-concept studies to over a dozen clinical trials for Alzheimer ’s disease (AD) and other tauopathies. Mechanistic studies in animal and culture models have provided valuable insight into how these therapies may work but multiple pathways are likely involved. Different groups have emphasized the importance of intracellular vs extracellular antibody-mediated cl earance of the tau protein and there is no consensus on which pool of tau should ideally be targeted. Likewise, various normal and disease-selective epitopes are being targeted, and the antibody isotypes eit...
Source: Drugs - June 8, 2021 Category: Drugs & Pharmacology Source Type: research

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions
AbstractNeisseria gonorrhoeae is the second most common bacterial sexually transmitted infection in the world afterChlamydia trachomatis. The pathogen has developed resistance to every antibiotic currently approved for treatment, and multidrug-resistant strains have been identified globally. The current treatment recommended by the World Health Organization is ceftriaxone and azithromycin dual therapy. However, resistance to azithromycin and ceftriaxone are increasing and treatment failures have been reported. As a result, there is a critical need to develop novel strategies for mitigating the spread of antimicrobial-resis...
Source: Drugs - June 7, 2021 Category: Drugs & Pharmacology Source Type: research

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015 –2020
AbstractIn the recent past, a plethora of drugs have been approved for the treatment of multiple sclerosis (MS). These therapeutics are mainly confined to immunomodulatory or immunosuppressive strategies but do not sufficiently address remyelination and neuroprotection. However, several neuroregenerative agents have shown potential in pre-clinical research and entered Phase I to III clinical trials. Although none of these compounds have yet proceeded to approval, understanding the causes of failure can broaden our knowledge about neuroprotection and neuroregeneration in MS. Moreover, most of the investigated approaches are...
Source: Drugs - June 4, 2021 Category: Drugs & Pharmacology Source Type: research

A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin ®) as a Resuscitative Agent in Hypovolemic Shock Patients
ConclusionCenthaquine is an efficacious resuscitative agent for treating hypovolemic shock. The efficacy of centhaquine in distributive shock is being explored.Trial RegistrationClinical Trials Registry, India; ctri.icmr.org.in, CTRI/2019/01/017196; clinicaltrials.gov, NCT04045327. (Source: Drugs)
Source: Drugs - June 1, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
The article Nintedanib: A Review in Fibrotic Interstitial Lung Diseases, written by Yvette N. Lamb, was originally published electronically in SpringerLink on 25 March 2021 without open access. (Source: Drugs)
Source: Drugs - May 29, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01542-w (Source: Drugs)
Source: Drugs - May 28, 2021 Category: Drugs & Pharmacology Source Type: research

Dasiglucagon: First Approval
This article summarizes the milestones in the development of dasiglucagon leading to this first approval for hypoglycaemia. (Source: Drugs)
Source: Drugs - May 28, 2021 Category: Drugs & Pharmacology Source Type: research

Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
(Source: Drugs)
Source: Drugs - May 28, 2021 Category: Drugs & Pharmacology Source Type: research

Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units
In this study, we report on resistance profiles ofEscherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis andEnterococcus faecium in distinct European geographic regions based on an observational cohort study on intra-abdominal infections in intensive care unit (ICU) patients. Resistance against aminopenicillins, fluoroquinolones, and third-generation cephalosporins inE. coli, K. pneumoniae andP. aeruginosa is problematic, as is carbapenem-resistance in the latter pathogen. ForE. coli andK. pneumoniae, resistance is mainly an issue in Central Europe, Eastern and South-East Europe, and Souther...
Source: Drugs - May 26, 2021 Category: Drugs & Pharmacology Source Type: research

Comment on: “Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Haemodialysis”
(Source: Drugs)
Source: Drugs - May 26, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01536-8 (Source: Drugs)
Source: Drugs - May 26, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Fostamatinib: A Review in Chronic Immune Thrombocytopenia
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01540-y (Source: Drugs)
Source: Drugs - May 26, 2021 Category: Drugs & Pharmacology Source Type: research

Lazertinib: First Approval
This article summarizes the milestones in the development of lazertinib leading to this first approval. (Source: Drugs)
Source: Drugs - May 24, 2021 Category: Drugs & Pharmacology Source Type: research

Evinacumab: First Approval
This article summarizes the mile stones in the development of evinacumab leading to this first approval for HoFH. (Source: Drugs)
Source: Drugs - May 18, 2021 Category: Drugs & Pharmacology Source Type: research

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
In conclusion, S1P modulators represent a novel and promising therapeutic strategy for immune-mediated diseases. (Source: Drugs)
Source: Drugs - May 13, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Inclisiran: First Approval
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01529-7 (Source: Drugs)
Source: Drugs - May 13, 2021 Category: Drugs & Pharmacology Source Type: research

Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia
AbstractLuspatercept (Reblozyl®), a first-in-class erythroid maturation agent, is approved in several countries worldwide for the treatment of adults with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS), who have failed prior erythropoiesis-stimulating therapy, or β-thalassaemia. In pivotal, placebo-controlled, phase III trials, subcutaneous luspatercept significantly reduced red blood cell (RBC) transfusion requirements in patients with MDS or β-thalassaemia. Luspatercept had a generally manageable tolerability profile in clinical trials. Adverse events of special interest include thromb...
Source: Drugs - May 10, 2021 Category: Drugs & Pharmacology Source Type: research

Fostamatinib: A Review in Chronic Immune Thrombocytopenia
AbstractFostamatinib (Tavalisse®; Tavlesse®) is the first spleen tyrosine kinase (Syk) inhibitor approved for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to previous treatment. By inhibiting Syk activation in macrophages, fostamatinib blocks autoantibody-mediated platelet phagocytosis. In the placebo-controlled phase  III FIT1 and FIT2 trials, 24 weeks of oral fostamatinib therapy increased platelet count in previously treated adults with ITP. A significantly higher proportion of patients achieved stable response with fostamatinib than wit...
Source: Drugs - May 10, 2021 Category: Drugs & Pharmacology Source Type: research

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
AbstractOral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodiumN-(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the acidic conditions of the stomach. Oral semaglutide is indicated for use as an add-on combination therapy (with other glucose-lowering agents, including insulin) or as a monotherapy (in patients who are intolerant to metformin) for typ...
Source: Drugs - May 8, 2021 Category: Drugs & Pharmacology Source Type: research

Melphalan Flufenamide (Melflufen): First Approval
This article summarizes the milestones in the development of melphalan flufenamide leading to this first approval. (Source: Drugs)
Source: Drugs - May 7, 2021 Category: Drugs & Pharmacology Source Type: research

Targeting AMPK by Statins: A Potential Therapeutic Approach
AbstractStatins are a group of lipid-lowering drugs that inhibit cholesterol biosynthesis and have anti-inflammatory, anti-tumor, and immunomodulatory properties. Several lines of evidence indicate that statins regulate multiple proteins associated with the regulation of differing cellular pathways. The 5 ′-adenosine monophosphate-activated protein kinase (AMPK) pathway plays an important role in metabolism homeostasis with effects on cellular processes including apoptosis and the inflammatory responses through several pathways. Recently, it has been shown that statins can affect the AMPK pathway i n differing physio...
Source: Drugs - May 3, 2021 Category: Drugs & Pharmacology Source Type: research

Ponesimod: First Approval
This article summarizes the milestones in the development of ponesimod leading to this first US approval. (Source: Drugs)
Source: Drugs - May 3, 2021 Category: Drugs & Pharmacology Source Type: research

Preclinical and Clinical Characteristics of the Trichuricidal Drug Oxantel Pamoate and Clinical Development Plans: A Review
AbstractSoil-transmitted helminths (Ascaris lumbricoides, hookworm andTrichuris trichiura) infect about one-fifth of the world ’s population. The currently available drugs are all highly efficacious againstA. lumbricoides. However, they are only moderately efficacious against hookworm and poorly efficacious againstT. trichiura. Oxantel, a tetrahydropyrimidine derivative discovered in the 1970s, has recently been brought back to our attention given its high efficacy againstT. trichiura infections (estimated 76% cure rate and 85% egg reduction rate at a 20 mg/kg dose). This review summarizes the current knowledge on ox...
Source: Drugs - April 30, 2021 Category: Drugs & Pharmacology Source Type: research

Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
AbstractThe obesity and type 2 diabetes mellitus epidemics demonstrate that  simply emphasizing a healthy lifestyle is insufficient. While weight loss medications have historically been considered “cosmetic”, glucagon-like peptide-1 receptor agonists (GLP1-RAs) also reduce cardiovascular risk in patients with type 2 diabetes. Therefore, we assessed whether GLP1-RAs war rant use in patients who are overweight (body mass index 27.0–29.9 kg/m2) without weight-related comorbidity. We reviewed trials of available GLP1-RAs with a natural GLP1 backbone given their trend toward cardiovascular benefit and exc...
Source: Drugs - April 30, 2021 Category: Drugs & Pharmacology Source Type: research

Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
AbstractEncorafenib (Braftovi®) is an oral small molecule BRAF inhibitor used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with aBRAF V600E mutation, who have received prior systemic therapy. In a clinical trial in adults withBRAF V600E-mutated mCRC who had disease progression after one or two previous regimens (BEACON CRC), encorafenib plus cetuximab was associated with a significantly longer median overall survival (OS), a higher objective response rate (ORR) and longer median progression-free survival (PFS), compared with standard therapy. Encorafenib plu...
Source: Drugs - April 29, 2021 Category: Drugs & Pharmacology Source Type: research

Fosdenopterin: First Approval
This article summarizes the milestones in the development of fosdenopterin leading to this first approval. (Source: Drugs)
Source: Drugs - April 28, 2021 Category: Drugs & Pharmacology Source Type: research

IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses
AbstractChronic pruritus is a debilitating symptom with limited treatment options. Identifying molecular targets underlying chronic pruritic dermatoses is essential for the development of novel, targeted therapies. IL-31 is an important mediator of itch by integrating dermatologic, neural, and immune systems. IL-31 helps induce and maintain chronic pruritus via both indirect stimulation of inflammatory cells and through direct neural sensitization. IL-31 is overexpressed in various chronic pruritic skin conditions, and exogenous IL-31 induces itch and scratching behavior. Studies have demonstrated that IL-31R and IL-31 ant...
Source: Drugs - April 21, 2021 Category: Drugs & Pharmacology Source Type: research

Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma
In conclusion, combination therapy with indacaterol/glycopyrronium/mometasone represents a valuable option for the maintenance treatment of asthma, with the convenience of once-daily admin istration via a single inhaler. (Source: Drugs)
Source: Drugs - April 19, 2021 Category: Drugs & Pharmacology Source Type: research

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
AbstractEntrectinib (Rozlytrek®) is an orally active, CNS-penetrant, small-molecule, selective inhibitor of the tropomyosin receptor tyrosine kinases TRKA/B/C [encoded by the neurotrophic tyrosine receptor kinase (NTRK) genesNTRK1/2/3, respectively], the proto-oncogene tyrosine-protein kinase  ROS1 (ROS1) and the anaplastic lymphoma kinase gene (ALK). It is approved for the treatment of adults and paediatric patients aged ≥ 12 years withNTRK fusion-positive (NTRK+) solid tumours and adults withROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC). In trials in adults, entrectinib induced clinical...
Source: Drugs - April 19, 2021 Category: Drugs & Pharmacology Source Type: research

Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
AbstractThe plasma cell neoplasm multiple myeloma (MM) is currently considered incurable. However, significant advances in treatment options over the past 20 years have led to unprecedented response rates to initial therapy as well as prolonged survival rates. Induction regimens have evolved from alkylator-based therapies to those consisting of immunomodulatory drugs and proteasome inhibitors. The combination of bortezomib/lenalidomide/dexamethasone (VRd) has emerged as a standard regimen for both transplant-eligible (TE) and transplant-ineligible (TI) patient populations. More recent efforts have focused on the incorporat...
Source: Drugs - April 19, 2021 Category: Drugs & Pharmacology Source Type: research

Givosiran: A Review in Acute Hepatic Porphyria
AbstractGivosiran (Givlaari®) is an δ-aminolevulinic acid synthase 1 (ALAS1)-directed small interfering RNA (siRNA) approved for the treatment of acute hepatic porphyria (AHP). In the phase 3 ENVISION trial, givosiran significantly reduced the annualized rate of composite porphyria attacks (i.e. attacks requiring hospitalization, urg ent healthcare visit or intravenous hemin administration at home) compared with placebo in patients with recurrent acute intermittent porphyria (the most common type of AHP) attacks. Givosiran also improved several other outcomes, including hemin use and pain (the cardinal symptom of...
Source: Drugs - April 19, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
The article Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome, written by Yahiya Y. Syed, was originally published electronically in SpringerLink on 18 March 2021 without open access. (Source: Drugs)
Source: Drugs - April 19, 2021 Category: Drugs & Pharmacology Source Type: research

Trilaciclib: First Approval
AbstractTrilaciclib(Cosela ™) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and trilaciclib induces a transient, reversible G1 cell cycle arrest of proliferating haematopoietic stem and progenitor cells in bone marrow, thus protecting them from damage during chemotherapy. In February 2021, trilaciclib received its first approval in the USA to decrease the incidence of chemotherapy-induced myelosup...
Source: Drugs - April 16, 2021 Category: Drugs & Pharmacology Source Type: research

Casimersen: First Approval
This article summarises the milestones in the development of casimersen leading to this first approval for DMD. As with other approvals under the Accelerated Approval Program, continued approval for this indication may be contingent upon verification of a clinical benefit in confirmator y trials. (Source: Drugs)
Source: Drugs - April 16, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Secukinumab: A Review in Psoriatic Arthritis
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01513-1 (Source: Drugs)
Source: Drugs - April 15, 2021 Category: Drugs & Pharmacology Source Type: research

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
A correction to this paper has been published: https://doi.org/10.1007/s40265-021-01519-9 (Source: Drugs)
Source: Drugs - April 13, 2021 Category: Drugs & Pharmacology Source Type: research

Pharmacotherapy for Nonconvulsive Seizures and Nonconvulsive Status Epilepticus
AbstractMost seizures in critically ill patients are nonconvulsive. A significant number of neurological and medical conditions can be complicated by nonconvulsive seizures (NCSs) and nonconvulsive status epilepticus (NCSE), with brain infections, hemorrhages, global hypoxia, sepsis, and recent neurosurgery being the most prominent etiologies. Prolonged NCSs and NCSE can lead to adverse neurological outcomes. Early recognition requires a high degree of suspicion and rapid and appropriate duration of continuous electroencephalogram (cEEG) monitoring. Although high quality research evaluating treatment with antiseizure medic...
Source: Drugs - April 8, 2021 Category: Drugs & Pharmacology Source Type: research

Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
AbstractIt is generally recommended that medications only be used in pregnancy where the potential harms to both the mother and foetus are outweighed by the potential benefits. Despite the known harms associated with alcohol consumption during pregnancy, the use of medication for the treatment of pregnant women with an alcohol use disorder (AUD) appears to be rare. This is likely due to the lack of available data regarding the safety of these medications in pregnancy. We reviewed the literature and weighed up the harms associated with alcohol use and AUD during pregnancy with the potential benefits of medications for AUD i...
Source: Drugs - April 8, 2021 Category: Drugs & Pharmacology Source Type: research

Umbralisib: First Approval
This article summarizes the milestones in the development of umbralisib leading to this first approval. (Source: Drugs)
Source: Drugs - April 2, 2021 Category: Drugs & Pharmacology Source Type: research

Surufatinib: First Approval
This article summarizes the milestones in the development of surufatinib leading to this first approval for extrapancreatic NET. (Source: Drugs)
Source: Drugs - March 31, 2021 Category: Drugs & Pharmacology Source Type: research

Ocular Toxicity of Targeted Anticancer Agents
AbstractThe proliferation of targeted anticancer agents over the last two decades has revolutionized cancer treatment and improved survival in many previously refractory malignancies. However, many agents are associated with characteristic ophthalmic adverse effects. It is important that ophthalmologists recognize and maintain a high index of suspicion for these side effects in patients on targeted therapy. Most ophthalmic adverse effects can be treated with specific ocular therapy without discontinuation of cancer treatment, although it is important to be aware of the life-threatening and vision-threatening circumstances ...
Source: Drugs - March 31, 2021 Category: Drugs & Pharmacology Source Type: research

Voclosporin: First Approval
This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis. (Source: Drugs)
Source: Drugs - March 31, 2021 Category: Drugs & Pharmacology Source Type: research

Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells
AbstractMantle cell lymphoma is a rare B-cell non-Hodgkin ’s lymphoma that retains a sobering prognosis despite an extensive research effort. Mantle cell lymphoma remains incurable even with aggressive, and at times toxic, chemoimmunotherapy with early incorporation of autologous stem cell transplantation. Given this, attention has turned to the use of t argeted therapies addressing dysregulation of B-cell signaling pathways. Drugs such as immunomodulatory agents, proteasome inhibitors, and Bruton’s tyrosine kinase inhibitors have shown success in the relapsed/refractory population, and there is ongoing investi...
Source: Drugs - March 30, 2021 Category: Drugs & Pharmacology Source Type: research

Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry
AbstractBackgroundThe impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization.MethodsThis work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19...
Source: Drugs - March 29, 2021 Category: Drugs & Pharmacology Source Type: research

Vericiguat: First Approval
AbstractVericiguat (VERQUVO ™; Merck& Co, Bayer AG) is a soluble guanylate cyclase (sGC) stimulator being developed for the treatment of chronic heart failure. Vericiguat stimulates sGC and cGMP production independent of nitric oxide (NO) and enhances the effects of NO by stabilizing the NO-sGC binding. Based on the results of the phase III VICTORIA trial vericiguat was recently approved in the USA for risk reduction in patients with heart failure and ejection fraction
Source: Drugs - March 26, 2021 Category: Drugs & Pharmacology Source Type: research

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
AbstractProgressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev®), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity...
Source: Drugs - March 25, 2021 Category: Drugs & Pharmacology Source Type: research